Alder Hits $15 Million BMS Milestone

Anti-IL-6 MAb goes into Phase IIb

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alder Biopharmaceuticals will receive a $15 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase IIb clinical trial in rheumatoid arthritis for ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6). The milestone payment is part of the Alder/BMS collaboration that was formed in 2009 for the development of ALD518/BMS-945429. Alder granted to BMS worldwide exclusive rights to develop and commercialize ALD518/BMS-945429 for all pot...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters